Torrent Pharmaceuticals reported a 42% YoY rise in Q4 FY26 consolidated revenue to ₹4,197 crores, with operating EBITDA at ₹1,356 crores.
The Board recommended a final dividend of ₹9 per share and approved seeking enabling approval for a ₹5,000 crore fundraising via QIP.
The results include the first quarter of consolidation for the acquired JB Chemicals & Pharmaceuticals, completed in January 2026 for ₹12,537 crores.
Standalone net profit for the quarter was ₹467 crores, while consolidated net profit attributable to owners was ₹389 crores.